Finally, the PALMIRA trial, which was an international, multicenter, randomized, open-label, phase II trial was conducted, aiming to evaluate the efficacy of continuation of palbociclib combined with second-line ET in patients with HR+/HER2− advanced breast cancer after disease progression on palbociclib-based first-line combination with ET (25). This evidence concerns the gene HR and breast carcinoma.